The present application provides for compositions comprising &alpha-galactosidase A in combination with an active site-specific chaperone for the &alpha-galactosidase A, and methods for treating Fabry disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an &alpha-galactosidase A enzyme formulation.
